- Home
- GSHD vs KALV Comparison
GSHD vs KALV Comparison
Compare GSHD & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GSHD | KALV |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | United States |
| Employees | 1600 | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 986.6M | 1.0B |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GSHD | KALV |
|---|---|---|
| Price | $41.99 | $26.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $72.50 | $32.60 |
| AVG Volume (30 Days) | 361.0K | ★ 5.4M |
| Earning Date | 04-22-2026 | 07-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $365,304,000.00 | $50,000,000.00 |
| Revenue This Year | $16.40 | $185.42 |
| Revenue Next Year | $18.53 | $59.23 |
| P/E Ratio | $40.75 | ★ N/A |
| Revenue Growth | 16.15 | ★ 495.66 |
| 52 Week Low | $35.84 | $9.83 |
| 52 Week High | $113.00 | $26.85 |
Technical Indicators
Market Signals| Indicator | GSHD | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 74.68 |
| Support Level | $39.99 | $14.25 |
| Resistance Level | $46.40 | $26.85 |
| Average True Range (ATR) | 2.46 | 0.07 |
| MACD | 0.25 | -0.22 |
| Stochastic Oscillator | 65.12 | 71.05 |
Price Performance
Historical ComparisonAbout GSHD Goosehead Insurance Inc.
Goosehead Insurance Inc operates as an insurance agency. Its insurance products consist of homeowner's insurance; auto insurance; other personal lines products including flood, wind and earthquake insurance; excess liability or umbrella insurance; specialty lines insurance (motorcycle, recreational vehicle and other insurance); commercial lines insurance (general liability, property, and auto insurance for small businesses); and life insurance. Geographically, it operates in Texas, California, Illinois, Florida, and other regions. The company is has a single reportable segment: insurance distribution.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.